Pharmacogenomics in Stroke and Cardiovascular Disease Pharmacogenomics in Stroke and Cardiovascular Disease
This review provides an overview of the genetic variants that influence individual responses to aspirin, clopidogrel, warfarin, and statins and the clinical implications for stroke patients.Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION
Antiplatelet agent indobufen was noninferior to aspirin in combination with clopidogrel after coronary intervention on both efficacy and safety outcomes, with less mostly minor bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 28, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Clopidogrel Recall; COAPT Score; Pediatric Cardiologist's Child Porn
(MedPage Today) -- FDA advised that generic lots of atenolol and clopidogrel (Plavix) are under recall due to a label mix-up by manufacturer Golden State Medical Supply. LivaNova's LifeSPARC advanced circulatory support system has its controller... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 4, 2022 Category: Cardiology Source Type: news

Golden State Medical Supply, Inc. Issues a Voluntary Nationwide Recall of Atenolol 25 mg Tablets and Clopidogrel 75 mg Tablets Due to a Label Mix-up
Golden State Medical Supply, Incorporated (GSMS, Inc.) - Camarillo, CA has initiated a voluntary recall of the products listed in the table below because a report was received that a bottle containing Clopidogrel 75mg Tablets produced with lot# GS046745 was mislabeled as Atenolol 25mg Tablets. This (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 30, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Keeping Plavix After Short DAPT: Bleeding Benefit Emerges a Few Years After PCI
(MedPage Today) -- A shortened course of dual antiplatelet therapy (DAPT) after angioplasty was associated with reduced bleeding, with no significant uptick in ischemic events, over longer follow-up of the SMART-CHOICE trial. Patients undergoing... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 29, 2022 Category: Cardiology Source Type: news

Full - Dose Anticoagulation Beneficial for Critically Ill With COVID - 19
However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 16, 2022 Category: Cancer & Oncology Tags: Cardiology, Infections, Internal Medicine, Critical Care, Oncology, Pharmacy, Conference News, Source Type: news

PANTHER: Should Clopidogrel Become the'New Aspirin' in CAD? PANTHER: Should Clopidogrel Become the'New Aspirin' in CAD?
The PANTHER meta-analysis of trials comparing aspirin with clopidogrel or ticagrelor as antiplatelet monotherapy in coronary artery disease patients suggest that P2Y12 inhibitor therapy is more effective.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

What to Know About Peripheral Artery Disease —and Its Connection to Diabetes
When we think of clogged arteries, most of us think about the heart. “But buildup of fatty plaques can happen in any artery, including those that carry blood away from the heart,” says Dr. Samuel Kim, a preventive cardiologist and lipidologist at Weill Cornell Medicine in New York. The arteries that branch out and feed into our arms and legs make up the bulk of what we call peripheral arteries. And the narrowing in these vessels is referred to as peripheral artery disease (PAD), a common condition in which the legs or arms don’t receive sufficient blood flow. “Interestingly, arteries in our legs and...
Source: TIME: Health - August 11, 2022 Category: Consumer Health News Authors: Lala Tanmoy Das Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

Drug pricing regulator NPPA fixes retail prices of 84 drug formulations
Similarly, the price of Paracetamol and Caffeine has been fixed at Rs 2.88 per tablet. Besides, the price of one Rosuvastatin Aspirin and Clopidogrel capsule has been fixed at Rs 13.91.In a separate notification, NPPA said it has extended the revised ceiling price of liquid medical oxygen and oxygen inhalation (medicinal gas) till September 30 this year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 3, 2022 Category: Pharmaceuticals Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Making the Case for Tailored Selection of Antiplatelet Therapy Making the Case for Tailored Selection of Antiplatelet Therapy
Recent studies have shown significant variability in response to clopidogrel. Should platelet function and genotyping for patients being treated with clopidogrel be the norm?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 7, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

GI Injury by Aspirin or Clopidogrel Monotherapy vs. DAPT GI Injury by Aspirin or Clopidogrel Monotherapy vs. DAPT
A new study explores the mechanisms of mucosal injury and GI bleeding with differing antiplatelet regimens in patients undergoing PCI.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Benefit of Antiplatelets in Noncritical COVID: ACTIV-4a No Benefit of Antiplatelets in Noncritical COVID: ACTIV-4a
The P2Y12 inhibitor drugs ticagrelor or clopidogrel did not increase survival or time without organ support in noncritically ill, hospitalized patients with COVID-19 in the ACTIV-4a trial.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 16, 2021 Category: Neurology Tags: Cardiology News Source Type: news